>Date: Tue, 17 Nov 1998 17:33:26 -0800
>Reply-To: "ANGIOGEN: Current Research on Angiogenesis"
<ANGIOGEN@LISTSERV.ACOR.ORG>
>Sender: "ANGIOGEN: Current Research on Angiogenesis"
<ANGIOGEN@LISTSERV.ACOR.ORG>
>From: Gene Valberg <genevalberg@YAHOO.COM>
>Subject: Re: [ANGIOGEN] FWD : Re: Judah Folkman
>To: ANGIOGEN@LISTSERV.ACOR.ORG
>
>Kevin Dalley <kevind@RAHUL.NET> wrote:
>>
>> I'll add another trial. Thalidomide is also being tested in a Phase
>> II trial against some leukemias, including AML, and I believe CML. MD
>> Anderson is running these tests.
>
>Hello Kevin,
>
>You must not have seen the original chart that I posted on
>antiangiogenesis clinical trials as the big "T" is on it. I'll post it
>again at the end of this email. A comment about Oxigene's
>combretastatin not being on the chart started this discussion. I have
>had private emails with that poster and still do not find
>combretastatin registered in any FDA trial for cancer. The poster in
>question sent me an article that talked about phase I and II but they
>are not in the FDA database.
>
>All, let me know if you know an FDA trial for angiogenesis Tx. that is
>not below.
>
>Thanks,
>
>Gene Valberg
>
> Drugs that prevent new blood vessels from invading surrounding tissue:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug Sponsor Trial Mechanism For More Info
>
>Marimastat British Phase III Synthetic MMP 800-355-6957
> Biotech; against inhibitor
> Annapolis, MD pancreas, non
> small cell
> lung, breast
> cancers
>Bay 12-9566 Bayer; West Phase III Synthetic 800-442-4950
> Haven, CT against lung inhibitor of
> and pancreatic tumor growth.
> cancers.
>AG3340 Agouron; 2 trials – Synthetic MMP 888-849-6482
> LaJolla, CA Phase III inhibitor
> against lung
> and against
> prostate
> cancers.
>MMI270 Novartis; East Phase I Synthetic MMP 973-781-2791
> Hanover, NJ inhibitor.
>COL-3 Collagenex; Phase I Synthetic MMP 800-4-CANCER
> Newtown, PA/ inihibitor.
> NCI Tetracycline
> derivative.
>Vitaxin Ixsys, Inc.; Phase II Antibody to 619-597-4990
> LaJolla, CA enrollment integrin, x106
> will begin in present on
> early-1999 endothelial
> cell surface.
>
>
>
> Natural inhibitors of angiogenesis:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug Sponsor Trial Mechanism For More Info
>
>Interleukin-12 Genetics Phase I/II Inhibits
>1-800-4-CANCER
> Institute; endotheliel cell
> Cambridge, growth
> MA
>RhuMAb, Genentech; Phase II/III Monoclonal 650-225-5300
>VEGF, and South San against lung, antibody to
>Anti-VEGF Francisco, breast, vascular
> CA prostate, endotheliel
> colorectal growth factor
> (VEGF)
>SU5416 Sugen, Inc.; Phase I and Molecule that 650-306-7678
> Redwood Phase I/II blocks VEGF
> City, CA for kaposi’s receptor
> sarcoma signaling
>SU101 Sugen, Inc: Phase III Molecule 650-306-7678
> against inhibitor that
> Redwood glioblastoma, blocks the
> City, CA and brain signaling of the
> cancers.
> Phase II platelet-derived
> against growth factor
> glioblastoma, (PDGF) receptor.
> and Phase II
> against
> ovarian
> cancer.
>Interferon Commercially Phase II/III Molecule that
>1-800-4-CANCER
>-alfa Available blocks VEGF
> receptor
> signaling
>
> Interrupts function of dividing endothelial cells:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug Sponsor Trial Mechanism
>
>TNP-470 TAP Phase II Synthetic
> Pharmaceuticals, against analogue of
> Deerfield, IL advanced cancer fungal protein;
> for adults with inhibits
> solid tumors. endotheliel
> cell growth
>
>Unknown mechanism; inhibits angiogenesis in laboratory and animal
>assays:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug Sponsor Trial Mechanism For More
>
>Thalidomide Entremed, Inc.; Phase II Synthetic 301-217-9858
> Rockville, MD against sedative
> Kaposi’s
> sarcoma,
> breast,
> prostate and
> primary brain
> cancers
>CAI NCI; Phase II Non-specific 800-4-CANCER
> Bethesda, MD against inhibitor cell
> refractory or invasion and
> recurrent motility
> ovarian
> epitheliel,
> fallopian
> tube, and
> primary
> peritoneal
> cancer; Phase
> I against
> refractory,
> recurrent or
> advanced
> cancers
>Squalamine Magainin Phase I Extract from 210-616-5798
> Pharmaceuticals, dogfish shark
> Inc.; Plymouth liver; inhibits
> Meeting, PA sodium-hydrogen
> exchanger, NHE3
>IM862 Cytran; Phase III Unknown 425-889-5808
> Kirkland, WA trial against mechanism
> AIDS-related
> Kaposi’s
> sarcoma.
> Enrollment
> will begin in
> November.
>
>_________________________________________________________
>DO YOU YAHOO!?
>Get your free @yahoo.com address at http://mail.yahoo.com
>
>
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
